Imfinzi 50 mg (Durvalumab SOLUTION) 50 MG

IMFINZI 50 MG is a solution for intravenous use, containing durvalumab. This medication is used in cancer treatment and is manufactured by AstraZeneca Canada Inc.

Strength

50 MG

Pack Size

2.4ML/10ML

Manufacturer / TM Owner

ASTRAZENECA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

IMFINZI 50 MG is primarily used in the treatment of certain types of cancer. Durvalumab, the active ingredient, works by targeting specific proteins involved in cancer cell growth. This medication is often prescribed as part of a broader cancer treatment plan, including what is durvalumab used for in advanced cancer therapies.

Side Effects

Common effects of IMFINZI 50 MG may include fatigue, nausea, and skin reactions at the injection site. Some individuals may also experience appetite loss or shortness of breath. These effects can vary depending on the individual and the specific cancer treatment plan.

Precautions & Warnings

IMFINZI 50 MG should be handled with care and administered by healthcare professionals. It is important to follow the prescribed dosage and administration guidelines. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting treatment.

Avoid Interactions

IMFINZI 50 MG may interact with other medications, including those that affect the immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of durvalumab.

Frequently Asked Questions

IMFINZI 50 MG is used in the treatment of certain types of cancer, often as part of a broader cancer treatment plan.

IMFINZI 50 MG is administered intravenously by healthcare professionals.

Common side effects may include fatigue, nausea, and skin reactions at the injection site.

It is important to discuss all current medications with a healthcare provider to avoid potential interactions.

IMFINZI 50 MG is manufactured by AstraZeneca Canada Inc.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.